Tranexamic Acid for Urethral Stricture
(REDUCER Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will test whether tranexamic acid (TXA), a medication used to reduce bleeding, can decrease blood loss in patients having urethroplasty. Participants will be randomly assigned to receive either a single intravenous dose of TXA at the start of anesthesia or standard care without TXA. Researchers will compare hemoglobin change after surgery as well as estimated blood loss and complications.
Who Is on the Research Team?
Amjad Alwaal, MD, MSc, FACS
Principal Investigator
Rutgers University
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intravenous dose of tranexamic acid (TXA) at the start of anesthesia or standard care without TXA during urethroplasty
Follow-up
Participants are monitored for safety and effectiveness after treatment, including routine clinical follow-up and assessment of postoperative complications
What Are the Treatments Tested in This Trial?
Interventions
- Tranexamic Acid
- Urethroplasty
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Participants undergoing urethroplasty will receive tranexamic acid (TXA) administered perioperatively in addition to standard surgical care.
Participants undergoing urethroplasty will receive standard surgical care without tranexamic acid.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Amjad Alwaal, MD, MSc, FRCSC, FACS
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.